PDS Biotech outlines trial protocol amendment for accelerated PFS endpoint in HPV16-positive cancer
Source: SeekingAlpha
2025-11-13 10:12:24 ET
More on PDS Biotechnology
- PDS Biotechnology Corporation (PDSB) Q3 2025 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on PDS Biotechnology
- Historical earnings data for PDS Biotechnology
- Financial information for PDS Biotechnology
Read the full article on Seeking Alpha
For further details see:
PDS Biotech outlines trial protocol amendment for accelerated PFS endpoint in HPV16-positive cancer
PDS Biotechnology Corporation
NASDAQ: PDSB
PDSB Trading
-2.48% G/L:
$0.6436 Last:
113,368 Volume:
$0.65 Open:
PDSB Latest News
February 20, 2026 08:30:00 am
PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval
January 28, 2026 08:45:00 am
PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI
January 22, 2026 08:45:00 am
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101
January 12, 2026 10:35:00 am
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026
PDSB Stock Data
$35,486,232
44,474,119
0.07%
12
N/A
Biotechnology & Life Sciences
Healthcare
US
Princeton
